Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 968.00 |
| Open | 970.00 |
| Bid | 972.41 x 100 |
| Ask | 973.87 x 100 |
| Day's Range | 966.85 - 979.98 |
| 52 Week Range | 684.81 - 998.33 |
| Volume | |
| Avg. Volume | 460,687 |
| Market Cap | 107.299B |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | 28.74 |
| EPS (TTM) | 33.88 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1,053.60 |
Simply Wall St.Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock continues to impress, up 3.2% over the past week
Key Insights Institutions' substantial holdings in Regeneron Pharmaceuticals implies that they have significant...
- Thomson Reuters StreetEvents
Q1 2024 Intellia Therapeutics Inc Earnings Call
Q1 2024 Intellia Therapeutics Inc Earnings Call
GlobeNewswireLatest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing Phase 1/2 CHORD trial is currently enrolling infants and children in the U.S., UK and Spain TARRYTOWN, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) wi
© 2024 Yahoo. All rights reserved.